Indivior: U.S. Court Finds No Patent Violation in Rivals' Generic Medicine
July 15 2019 - 9:33AM
Dow Jones News
By Carlo Martuscelli
Indivior PLC (INDV.LN) said Monday that a U.S. court ruled that
Dr. Reddy's Laboratories Ltd. (500124.BY) and Alvogen Inc.
(AVGN.XX) had not infringed on a patent for its Suboxone film
anti-opioid addiction medication.
The two companies brought generic treatments to market for
opioid addiction in February. The court decision confirms that
these products aren't in violation of Indivior's patented
product.
The U.S. court did rule against a third rival, Actavis
Laboratories UT, Inc., which is barred from selling its product
until the patent expiry in 2024.
Indivior shares at 1351 GMT were down 2.55 pence, or 5.80%, to
43.22 pence.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 15, 2019 10:18 ET (14:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2024 to May 2024
Indivior (LSE:INDV)
Historical Stock Chart
From May 2023 to May 2024